Moderna is seeking authorization from the US Food and Drug Administration for a second booster of its SARS-CoV-2 vaccine for all adults, the Washington Post reports.
This, the Post notes, is a wider request than the one made earlier this week by Pfizer and BioNTech. Those companies are seeking an EUA for a second booster of their vaccine for individuals who are 65 or older or are immunocompromised.
Currently, a booster of Moderna's SARS-CoV-2 vaccine is available to all adults aged 18 and older a few months following their initial vaccination. According to the Post, the company is seeking a second booster in response to concerns that the protection conferred by the vaccine may decline.
The New York Times adds that Moderna cites data from the US and Israeli on how its vaccine fared against the Omicron variant as well as Centers for Disease Control and Prevention in its application. The CDC data suggested that both the Moderna and Pfizer-BioNTech vaccines had a drop in protection against hospitalization, falling from 91 percent to 78 percent after four months, it adds.